Mastrangelo Mj
- Oncology top 10%
- Immunology
- Molecular Biology
- Ophthalmology top 5%
- Radiology, Nuclear Medicine and Imaging
- Co-authors
- David BerdHarris DtHenry MaguireShields ClTakahiko SatoMagüire HcShoei‐Sheng LeeEdward F. McClay
- Topics
- Immunotherapy and Immune Responses (6 papers)Melanoma and MAPK Pathways (6 papers)Cutaneous Melanoma Detection and Management (5 papers)
- Cited by
- ImmunologyOncologyOphthalmology
- Journals
- PubMed
- Partner nations
- United States
In The Last Decade
Mastrangelo Mj
21 papers receiving 433 citations
Peers
Comparison fields: 5 of 70
- Oncology 233
- Immunology 198
- Molecular Biology 170
- Ophthalmology 62
- Radiology, Nuclear Medicine and Imaging 54
Countries citing papers authored by Mastrangelo Mj
This map shows the geographic impact of Mastrangelo Mj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mastrangelo Mj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mastrangelo Mj more than expected).
Fields of papers citing papers by Mastrangelo Mj
This network shows the impact of papers produced by Mastrangelo Mj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mastrangelo Mj. The network helps show where Mastrangelo Mj may publish in the future.
Co-authorship network of co-authors of Mastrangelo Mj
This figure shows the co-authorship network connecting the top 25 collaborators of Mastrangelo Mj. A scholar is included among the top collaborators of Mastrangelo Mj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mastrangelo Mj. Mastrangelo Mj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. | 64 |
| 2 | Active specific immunization in the treatment of patients with melanoma. | 24 |
| 3 | In situ cytokine gene transfection using vaccinia virus vectors. | 30 |
| 4 | Adjuvant therapy for cutaneous melanoma. | 3 |
| 5 | Theory and application of early systemic therapy. | 27 |
| 6 | Systemic chemotherapy for metastatic melanoma. | 46 |
| 7 | Allergy-induced hepatic toxicity associated with dacarbazine. | 20 |
| 8 | Assessment of survival rates with metastatic malignant melanomas. | 6 |
| 9 | The immunoaugmenting effects of cancer chemotherapeutic agents. | 34 |
| 10 | Current condition and prognosis of tumor immunotherapy: a second opinion. | 13 |
| 11 | Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. | 6 |
| 12 | Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. | 28 |
| 13 | Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. | 15 |
| 14 | Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma. | 5 |
| 15 | Clinical and immunological significance of human melanoma cytotoxic antibody. | 56 |
| 16 | Bacillus Calmette-Guerin in the treatment of neoplastic disease. | 34 |
| 17 | Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816). | 19 |
| 18 | Immunotherapy of melanoma with intralesional BCG. | 35 |
| 19 | Phase I study of ICRF-159 (NSC-129943) in human solid tumors. | 4 |
| 20 | Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease. | 2 |
About Mastrangelo Mj
Mastrangelo Mj is a scholar working on Oncology, Immunology and Biotechnology, having authored 21 papers that have together received 476 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (6 papers), Melanoma and MAPK Pathways (6 papers) and Cutaneous Melanoma Detection and Management (5 papers). The work is most often cited by research in Immunology (198 citations), Oncology (233 citations) and Ophthalmology (62 citations). Mastrangelo Mj has collaborated with scholars based in United States. Frequent co-authors include David Berd, Harris Dt, Henry Maguire, Shields Cl, Takahiko Sato, Magüire Hc, Shoei‐Sheng Lee, Edward F. McClay, Darwin O. Chee and Tetsuo Satō. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.